TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02202616

Intervention type: DRUG
Group type: OTHER
Intervention: Glycopyrronium /Indacaterol maleate
Description: Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
Study: NCT00367458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg atorvastatin oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg atorvastatin oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients will be administered placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients will be administered placebo
Study: NCT01381640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: marketed formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental formulation
Study: NCT02334189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Patients receive an information letter following an avoidable visit to the Emergency Department.
Study: NCT00961415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75mg/m2 iv on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m2 iv on day 1 of each 3-week cycle
Study: NCT04636918

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine Ophthalmic
Description: Prospective interventional study (single arm)
Study: NCT01122355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid modification
Description: 1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid modification
Description: 1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
Study: NCT01193764

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% cocoa powder
Description: A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
Study: NCT00961415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500mg/m2 iv on day 1 of each 3-week cycle
Study: NCT04664387

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary angiography
Description: A coronary angiography is a test to find out if there is stenosis in coronary artery.

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary angiography
Description: A coronary angiography is a test to find out if there is stenosis in coronary artery.
Study: NCT04144829

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU
Description: Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin
Description: Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
Study: NCT00556959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose clonidine HCl sustained release
Description: high dose clonidine HCl sustained release tablets for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose clonidine HCl sustained release
Description: low dose clonidine HCl sustained release tablets for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets for 8 weeks
Study: NCT04619537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT02495675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannulas
Description: Comparison of different flow levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannulas
Description: Comparison of different flow levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannulas
Description: Comparison of different flow levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional flow via nasal prongs
Description: Low flow of air delivered through conventional nasal prongs
Study: NCT03361345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical tranexamic acid in cream form applied to dark spots on right side of face.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
Study: NCT03510936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
Study: NCT02990377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RL-supported IVR intervention
Description: Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
Study: NCT01193764

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: gelatin (Gelita)
Description: A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
Study: NCT00144885

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Modification of therapy
Description: Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
Study: NCT00719797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT04930939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training cardiac rehabilitation program
Description: Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
Study: NCT03318718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia with non-depolarizing NMBA Rocuronium
Description: Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TOF measurement
Description: TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MEP measurement
Description: MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
Study: NCT01277081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol hot drink
Description: Hot drink containing paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol tablets
Description: Paracetamol tablets
Study: NCT00420641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK372475
Description: GSK372475 1.0-1.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine 20-30 mg/day

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo to Match
Study: NCT04930939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training cardiac rehabilitation program
Description: Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
Study: NCT04009083

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care MRI
Description: Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine PET scan added to MRI
Description: 18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
Study: NCT03732924

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement
Description: To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement
Description: To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
Study: NCT02999503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Nutritional education trough a personal online nutritional consultant
Study: NCT03736707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective HFOV
Description: Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
Study: NCT01203488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
Study: NCT03736707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMV
Description: CMV was delivered by time-cycled, pressure-limited ventilators
Study: NCT01076127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketllebell training
Description: Kettlebell training 3 x 20 min a week for 8 weeks

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Receives a health examination before and after the intervention period, and are advised to stay active.
Study: NCT00048087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: 250 mg by mouth daily each day for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
Study: NCT01203488

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Control infants received a sham procedure rather than placebo injections.
Study: NCT04649983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 and CD22 targeted CAR-T cells
Description: A single infusion of CD19 and CD22 CAR-T cells will be administered intravenously
Study: NCT02749890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic drugs
Description: Pharmaceutical form: tablet~Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anti-diabetic drugs
Description: Pharmaceutical form: tablet~Route of administration: Oral
Study: NCT00908778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitreosolve
Description: intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitreosolve
Description: intravitreal injection
Study: NCT03156140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion
Description: Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
Study: NCT03459586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 9zest app facilitated exercise
Description: The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
Study: NCT00585182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg once daily
Description: Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
Study: NCT06397638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue carotid stenting
Description: Rescue carotid stenting in tandem occlusions
Study: NCT03390153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi flexible socket
Description: The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rigid fiber socket
Description: The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
Study: NCT01104766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study: NCT04256499

Intervention type: PROCEDURE
Intervention: Acute water load test
Description: The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.

Intervention type: PROCEDURE
Intervention: Acute water load test
Description: The acute water load test consists in administering orally 20 mL/kg (of body weight) of water (ingested in less than 30 min) and then follow (during 4 to 6 hours) blood and urine parameters.
Study: NCT01251458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel
Description: Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
Study: NCT01651884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS (Soterix)
Description: Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (Neuroconn)
Study: NCT01341470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously or subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously or subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously or subcutaneously
Study: NCT01636037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (generic version of Sinemet)
Description: Oral levodopa 900mg daily as tolerated.
Study: NCT01341470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: administered intravenously or subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intravenously or subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intravenously or subcutaneously
Study: NCT02909595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon catheter
Description: Balloon stone extraction was carried out with a balloon catheter \[Extractor Pro RX \[M00547000, M00547010, or M00547020\]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basket catheter
Description: Basket stone extraction was performed with a basket catheter (Flower Basket V \[FG-V435P or FG-V425PR\]; Olympus Corp., Shang hai,China).
Study: NCT02558569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: L form of bupivacaine with less cardiotoxicity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: NSS
Description: Clear intravenous fluid looks alike local anesthetic.
Study: NCT04452006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 10 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541478 30 mg
Description: ACT-541478 will be provided in HPMC capsules for oral administration at a dose strength of 10 mg.
Study: NCT01818934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip ultrasound
Description: Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
Study: NCT01818934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip ultrasound
Description: Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip ultrasound
Description: Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
Study: NCT03817346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GT-002
Description: Single ascending dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Comparator single ascending dose
Study: NCT02120846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flywheel leg-press resistance exercise
Study: NCT03179631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: 10, 20 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 10, 20 mg/kg